Overview

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
This phase II study is to evaluate the efficacy of the adjuvant immunotherapy after curative-intent ablation for recurrent hepatocarcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Xiangya Hospital of Central South University